CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 3
Abstract
The Nanotechnology Risk Assessment Working Group in the Center for Drug Evaluation and Research (CDER) within the United States Food and Drug Administration was established to assess the possible impact of nanotechnology on drug products. The group is in the process of performing risk assessment and management exercises. The task of the working group is to identify areas where CDER may need to optimize its review practices and to develop standards to ensure review consistency for drug applications that may involve the application of nanotechnology. The working group already performed risk management exercises evaluating the potential risks from administering nanomaterial active pharmaceutical ingredients (API) or nanomaterial excipients by various routes of administration. This publication outlines the risk assessment and management process used by the working group, using nanomaterial API by the oral route of administration as an example.
Authors and Affiliations
Celia N. Cruz, Katherine M. Tyner, Lydia Velazquez, Kenneth C. Hyams, Abigail Jacobs, Arthur B. Shaw, Wenlei Jiang, Robert Lionberger, Peter Hinderling, Yoon Kong, Paul C. Brown, Tapash Ghosh, Caroline Strasinger, Sandra Suarez-Sharp, Don Henry, Maat Van Uitert, Nakissa Sadrieh, Elaine Morefield
Keywords
Related Articles
- EP ID EP681121
- DOI 10.1208/s12248-013-9466-6
- Views 51
- Downloads 0
Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy
The superfamily of organic anion-transporting polypeptides (OATPs, gene symbol SLCO) includes important transporters handling a variety of endogenous and xenobiotic substrates. Currently, 11 human OATPs are known and the...
Conformational Analysis of Therapeutic Proteins by Hydroxyl Radical Protein Footprinting
The online version of this article (doi:10.1208/s12248-012-9336-7) contains supplementary material, which is available to authorized users.
Intellectual property policy in the pharmaceutical sciences: The effect of inappropriate patents and market exclusivity extensions on the health care system
Though patents are effective tools for promoting innovation and protecting intellectual property in the pharmaceutical sciences, there has been growing concern about 2 important ways that patents in this field can have a...
Evaluation of Estimation Methods and Power of Tests of Discrete Covariates in Repeated Time-to-Event Parametric Models: Application to Gaucher Patients Treated by Imiglucerase
Analysis of repeated time-to-event data is increasingly performed in pharmacometrics using parametric frailty models. The aims of this simulation study were (1) to assess estimation performance of Stochastic Approximatio...
Release Behaviour of Single Pellets and Internal Fine 3D Structural Features Co-define the In Vitro Drug Release Profile
Multi-pellet formulations are advantageous for the controlled release of drugs over single-unit dosage forms. To understand the diffusion controlled drug release mechanism, the pellet structure and drug release from a si...